GW Pharma had a US$2.9 billion market cap on the back of their phase 2 trials of CBD based drug, Epidiolex. Keep in mind Epidiolex was treating an orphan epilepsy condition so the market size was also constrained.
They were US$3.3 billion on completion of phase 3 trials and importantly still pre revenue.
Revenue ramped up dramatically in 2020 and we all know the outcome. Takeover in 2021 for US$7.4 billion by Jazz Pharma.
IMO, do not underestimate the value that IHL will create in the next 2 to 12 months, particularly with 5 clinical trials underway and each addressing a billion dollar market opportunity. OSA is clearly the flagship but each is a company marker.
- Forums
- ASX - By Stock
- IHL
- General discussion
General discussion, page-11863
-
-
- There are more pages in this discussion • 8,152 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IHL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, CEO
Paul Long
CEO
Previous Video
Next Video
SPONSORED BY The Market Online